|Product Candidate||Target Selection||Pre-clinical||Phase 1||Phase 2||Partner|
|CUE-101 Monotherapy 2L+ (HPV)||Asia Rights|
|CUE-101 KEYTRUDA 1L (HPV)||*|
|CUE-101 Neoadjuvant (HPV)|
|CUE-102 (WT1)||Asia Rights|
|Autoimmune & Inflammation|
* CUE-101 Combo Trial with KEYTRUDA®
Please visit our Partnering section for information on our Autoimmune and Inflammatory disease assets.
Cue Biopharma is advancing a pipeline of targeted interleukin 2 (IL-2)-based immunotherapies for multiple types of cancers with high unmet needs.
The CUE-100 series of biologics have the potential to improve efficacy and reduce the severe toxicities associated with non-specific IL-2 cancer immunotherapies. They are engineered to selectively engage and modulate tumor-specific immune T cells by taking advantage of the specificity already existing in nature, and avoid toxicities associated with indiscriminate immune activation.
Our lead clinical candidate, CUE-101, has already demonstrated clinical activity and favorable tolerability as a monotherapy in a Phase 1 trial in patients with human papilloma virus (HPV16+) recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). This validates the clinical applicability of our technology platforms and therapeutic potential of our advanced pipeline of biologics for the treatment of cancer.